X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (98) 98
hematology (55) 55
adult (53) 53
middle aged (50) 50
female (46) 46
male (44) 44
aged (39) 39
oncology (38) 38
imatinib mesylate (22) 22
index medicus (22) 22
benzamides (18) 18
chronic myeloid-leukemia (16) 16
pyrimidines - therapeutic use (16) 16
adolescent (15) 15
bcr-abl (15) 15
interleukin-3 - therapeutic use (15) 15
research (15) 15
antineoplastic agents - therapeutic use (14) 14
health aspects (14) 14
piperazines - therapeutic use (14) 14
recombinant proteins - therapeutic use (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (13) 13
treatment outcome (13) 13
bone marrow - pathology (12) 12
hematopoiesis (12) 12
myelodysplastic syndromes - therapy (12) 12
hematopoiesis - drug effects (11) 11
hematopoietic stem cells - drug effects (11) 11
leukemia (11) 11
aged, 80 and over (10) 10
cell biology (10) 10
chronic myelogenous leukemia (10) 10
drug therapy (10) 10
further section (10) 10
imatinib (10) 10
minimal residual disease (10) 10
myelodysplastic syndromes - drug therapy (10) 10
remission induction (10) 10
stem cells (10) 10
transplantation (10) 10
young adult (10) 10
acute lymphocytic leukemia (9) 9
animals (9) 9
care and treatment (9) 9
cells (9) 9
philadelphia chromosome (9) 9
progenitor cells (9) 9
prognosis (9) 9
acute lymphoblastic leukemia (8) 8
bone marrow (8) 8
chemotherapy (8) 8
chronic myeloid leukemia (8) 8
colony-stimulating factor (8) 8
differentiation (8) 8
drug administration schedule (8) 8
drug evaluation (8) 8
genetic aspects (8) 8
immunology (8) 8
inhibitor (8) 8
interleukin-3 - pharmacology (8) 8
myelodysplastic syndrome (8) 8
myelodysplastic syndromes - blood (8) 8
philadelphia-chromosome (8) 8
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (8) 8
precursor cell lymphoblastic leukemia-lymphoma - genetics (8) 8
recombinant proteins - pharmacology (8) 8
blast crisis (7) 7
cell division (7) 7
fusion proteins, bcr-abl - genetics (7) 7
myelodysplastic syndromes (7) 7
patient outcomes (7) 7
protein kinase inhibitors - therapeutic use (7) 7
protein-tyrosine kinases - antagonists & inhibitors (7) 7
recombinant proteins - adverse effects (7) 7
special section (7) 7
time factors (7) 7
tyrosine kinase (7) 7
acute lymphoblastic-leukemia (6) 6
acute myeloid-leukemia (6) 6
antineoplastic agents - administration & dosage (6) 6
antineoplastic agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
apoptosis (6) 6
bone marrow - drug effects (6) 6
bone marrow cells (6) 6
cells, cultured (6) 6
cml (6) 6
dose-response relationship, drug (6) 6
drug resistance, neoplasm (6) 6
hematopoietic stem cells - cytology (6) 6
interleukin-3 - adverse effects (6) 6
myelodysplastic syndromes - pathology (6) 6
nilotinib (6) 6
proliferation (6) 6
pyrimidines - administration & dosage (6) 6
risk factors (6) 6
salvage therapy (6) 6
sti571 (6) 6
abl tyrosine kinase (5) 5
acute lymphocytic-leukemia (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 06/2013, Volume 27, Issue 6, pp. 1254 - 1262
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 08/2013, Volume 27, Issue 8, pp. 1628 - 1636
Journal Article
Leukemia, ISSN 0887-6924, 2010, Volume 24, Issue 3, pp. 521 - 535
Journal Article
Leukemia, ISSN 0887-6924, 2017, Volume 31, Issue 12, pp. 2799 - 2806
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic... 
CONVENTIONAL CARE REGIMENS | RESPONSE CRITERIA | ONCOLOGY | HISTONE DEACETYLASE INHIBITION | DNA METHYLTRANSFERASE | VALPROIC ACID | ACUTE MYELOID-LEUKEMIA | TRANS-RETINOIC ACID | HEMATOLOGY | MYELODYSPLASTIC SYNDROME | EPIGENETIC CHANGES | INTERNATIONAL WORKING GROUP | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Leukemia, Myelomonocytic, Chronic - drug therapy | Indoles - administration & dosage | Aged, 80 and over | Hydroxamic Acids - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Leukemia, Myelomonocytic, Chronic - pathology | Myelodysplastic Syndromes - drug therapy | Azacitidine - administration & dosage | Administration, Oral | Leukemia, Myeloid, Acute - pathology | Leukemia, Myelomonocytic, Chronic - mortality | Kaplan-Meier Estimate | Treatment Outcome | Leukemia, Myeloid, Acute - mortality | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Myelodysplastic Syndromes - mortality | Aged | Myelodysplastic Syndromes - pathology | Care and treatment | Usage | Transplantation | Diagnosis | Myelodysplastic syndromes | Stem cells | Slopes | Myelomonocytic leukemia | Myeloid leukemia | Leukemia | Risk | Patients | Survival | Myelodysplastic syndrome | Optimization | Quality | Chronic myelomonocytic leukemia | Bone marrow | Adults | Acute myeloid leukemia | Original
Journal Article
Leukemia, ISSN 0887-6924, 10/2005, Volume 19, Issue 10, pp. 1774 - 1782
BCR/ABL-kinase mutations frequently mediate clinical resistance to the selective tyrosine kinase inhibitor Imatinib mesylate (IM, Gleevec (R)). However,... 
mTOR inhibitor | Akt signaling | CML | BCR/ABL | Imatinib resistance | P13-kinase | CHRONIC MYELOGENOUS LEUKEMIA | MAMMALIAN TARGET | ABL TYROSINE KINASE | imatinib resistance | PI3-kinase | TRANSPLANT RECIPIENTS | CHRONIC MYELOID-LEUKEMIA | ONCOLOGY | PHILADELPHIA-CHROMOSOME | ACUTE LYMPHOBLASTIC-LEUKEMIA | CLINICAL RESISTANCE | RIBOSOMAL-PROTEIN S6 | MESYLATE STI571 | HEMATOLOGY | Protein Kinases - metabolism | Apoptosis - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Protein Kinases - chemistry | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - metabolism | RNA, Messenger - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Phosphorylation - drug effects | Tumor Cells, Cultured | Everolimus | Immunosuppressive Agents - pharmacology | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | Sirolimus - analogs & derivatives | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | RNA, Messenger - genetics | RNA, Small Interfering - pharmacology | Protein-Serine-Threonine Kinases - genetics | Proto-Oncogene Proteins - genetics | Piperazines - therapeutic use | Enzyme Activation - drug effects | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Sirolimus - pharmacology | Blotting, Western | Proto-Oncogene Proteins c-akt | Fusion Proteins, bcr-abl - genetics | Mutagenesis | Pyrimidines - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | TOR Serine-Threonine Kinases | Benzamides | Cell Cycle - drug effects | Fusion Proteins, bcr-abl - metabolism
Journal Article
Leukemia, ISSN 0887-6924, 07/2012, Volume 26, Issue 7, pp. 1475 - 1481
Imatinib is highly effective in newly diagnosed, but not in relapsed, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL). BCR-ABL... 
tyrosine kinase inhibitors | mutation | minimal residual disease | Ph+ ALL | resistance | BCR-ABL | STI571 | TYROSINE KINASE | Ph plus ALL | CHEMOTHERAPY | CHRONIC MYELOID-LEUKEMIA | POINT MUTATIONS | ONCOLOGY | PHILADELPHIA-CHROMOSOME | PH | INHIBITOR | HEMATOLOGY | ELDERLY-PATIENTS | Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology | Prevalence | Prognosis | Prospective Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Adult | Female | Philadelphia Chromosome | Real-Time Polymerase Chain Reaction | RNA, Messenger - genetics | Neoplasm Recurrence, Local - diagnosis | Piperazines - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis | Mutation - genetics | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Randomized Controlled Trials as Topic | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Recurrence, Local - epidemiology | Benzamides | Clinical Trials, Phase II as Topic | Gene mutations | Patient outcomes | Physiological aspects | Genetic aspects | Acute lymphocytic leukemia | Research | Drug therapy | Protein kinases
Journal Article
Haematologica, ISSN 0390-6078, 01/2015, Volume 100, Issue 3, pp. 392 - 399
Journal Article
Journal Article